Per Falholt is a Danish biotechnology executive, formerly head of research and development at Novozymes. His connection to the psychedelic field is participation in Octarine Bio’s €12.8 million Series A (closed January 2026), backing the Danish synthetic-biology company that produces pharmaceutical-grade psilocybin via engineered yeast fermentation.
Investor Context
Angel InvestorsInvestment Context
This stakeholder is listed as an Angel Investor within Angel Investors. Its public geography context is global. Public stage focus is not listed yet. Psychedelic-market posture: Psychedelic-Adjacent Focus.
Public Portfolio Examples
- Octarine BioSeries A (close) - €12.8 million total Series A (incl. €5 million new capital added Jan 2026) - Jan 22, 2026
Created from documented participation in 1 psychedelic financing round. Profile details beyond documented deals are unverified.
Investor Type
Angel Investor
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Stage focus is not listed yet.
Investment Focus Areas
Focus areas are not listed yet.
Recorded Investments
Jan 22, 2026
Series A (close) - €12.8 million total Series A (incl. €5 million new capital added Jan 2026)
Danish biotech Octarine Bio closes €12.8 million Series A for sustainable pigments